[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.79.246. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
February 2015

Moving Targets for Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

Author Affiliations
  • 1Department of Neurology, University of Utah, Salt Lake City
  • 2Department of Neurology, Mayo Clinic, Rochester, Minnesota
JAMA Neurol. 2015;72(2):147-149. doi:10.1001/jamaneurol.2014.3831

Stem cell transplant for multiple sclerosis (MS) has been a subject of great interest to scientists, physicians, and patients. The status of stem cell therapy is a common question posed by patients at their annual MS visit, usually as a parting query. Most patients have a vague concept of stem cell therapy, typically one that has been molded by a perception that stem cell therapy is regenerative. Therapies that promote regeneration of lost myelin and axons are all but absent from the current armamentarium of neurologists.

First Page Preview View Large
First page PDF preview
First page PDF preview
×